4 Analysts Assess OncoCyte: What You Need To Know
Portfolio Pulse from Benzinga Insights
Analysts have mixed ratings for OncoCyte (NASDAQ:OCX) with a recent trend towards bullish sentiment. The average 12-month price target has increased to $4.38, reflecting a 21.67% rise from the previous target. Key analysts have maintained or raised their ratings, indicating positive expectations for the stock.
May 16, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have mixed ratings for OncoCyte with a recent trend towards bullish sentiment. The average 12-month price target has increased to $4.38, reflecting a 21.67% rise from the previous target. Key analysts have maintained or raised their ratings, indicating positive expectations for the stock.
The recent trend in analyst ratings for OncoCyte is bullish, with an increase in the average 12-month price target. This suggests positive market sentiment and potential for short-term price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100